ADCETRIS

Despite very limited data, but given the high response rate and the absence of a validated therapeutic alternative, the Transparency Committee is of the opinion that ADCETRIS offers a moderate improvement in actual benefit (IAB III) in terms of efficacy in the treatment of adults

- with relapsed or refractory CD30+ Hodgkin lymphoma following autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.

- with relapsed or refractory systemic anaplastic large cell lymphoma.